Bausch Health Companies Inc., Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) and Prestige Consumer Healthcare, Inc. are Dominating the U.S. Warts Treatment Market in 2019

The U.S. Warts Treatment Market is expected to grow with the CAGR of 8.2% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access full Report @ https://www.databridgemarketresearch.com/reports/us-warts-treatment-market

The U.S. warts treatment market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in the U.S. warts treatment market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio. For instance, in February 2020, Bausch Health Companies Inc. launched a new telemedicine platform on Dermatology.com in the U.S. This website launch allows patients to consult with healthcare and physicians in order to receive prescription on demand for various dermatology products such as ALDARA, SOLODYN. ALDARA is an imiquimod cream which is used for warts treatment. This program launch helps the company to gain patients attention and also to increase awareness towards major warts treatment products.

Bausch Health Companies Inc. is the dominating player in the U.S. warts treatment market. The other key players existing in the market includes Dr. Reddy’s Laboratories Ltd., Almirall, S.A, Prestige Consumer Healthcare, Inc., CryoPen, Inc., EPI Health, Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Bako Diagnostics, CryoSurgery, Inc., Bristol-Myers Squibb Company, Perrigo Company plc, Fotona, Emblation Ltd., Nielsen Biosciences, Verrica Pharmaceuticals, Aclaris Therapeutics, Inc., Peritech Pharma, Nowarta Biopharma, Inc., Novan, Inc., Vaxart, Inc. among others.

Bausch Health Companies Inc.:

Bausch Health Companies Inc. headquartered in Quebec, Canada, mainly focuses on delivering their commitments to patients, health care providers, stakeholders and society. The company has multiple business segments including bausch + lomb international, salix, diversified products, and ortho dermatologics. In this ortho dermatologics is the market focused segment. The company has wide product portfolio such as dermatology products/aesthetics devices, gastrointestinal, eye health, generics, neurology and other, dentistry, consumer health, in which dermatology products/aesthetics devices is the market focused category.

  • In August 2018, Bausch Health Companies Inc. received FDA approval for new drug application filed for ALTRENO, which is the formulation of tretinoin and is used for warts treatment. This approval helped the company to expand its product portfolio for warts treatment which helped the company to generate more revenue through product sales.

The company has wide presence across Americas, Asia, Europe, and Middle East and Africa. The company also has various subsidiary companies such as Bausch & Lomb Argentina S.R.L. (Argentina), Bausch & Lomb (Australia) Pty Limited (Bausch & Lomb (Australia) Pty Limited), Private Formula International Holdings Pty Ltd (Australia), Valeant (Australia) Pty Limited (Australia) among others.

Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.):

Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) headquartered in New Jersey, U.S. was founded in 1891. The company focuses on innovation and scientific excellence in order to deliver medicines, vaccines and animal health products that can help millions around the world. The company has multiple business segments including pharmaceutical and animal health. In this pharmaceutical is the market focused segment. The company has wide product portfolio including prescription products, vaccines, oncology products, in which vaccines is the market focused category.

  • In October 2017, Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) achieved positive phase III result owing to efficacy and immunogenicity, for Gardasil 9 up to six years. This positive result helped the company to expand its product performance among users and hence allowed users to purchase Gardasil 9 for warts treatment.

The company has its presence in North America.

Prestige Consumer Healthcare, Inc.:

Prestige Consumer Healthcare, Inc. headquartered in Virginia, U.S. was founded in 1996. The company focuses on product innovation and quality in the over-the-counter healthcare category to provide better improved lives to their customers. The company has multiple business segments including North America OTC healthcare, International OTC healthcare and household cleaning. In this North America OTC healthcare is the market focused segment. The company is engaged in providing wide range of product categories such as digestive care, eye, ear, nose & throat, oral care, pain relief, pediatric care, skin care, sleep aids, women's health in which skin care is the market focused product category.  

  • In February 2016, Prestige Consumer Healthcare, Inc. completed acquisition of DenTek Holdings, Inc. This acquisition helped the company to expand its portfolio of iconic brands which also involved compound W Nitrofreeze, a product used for warts treatment.

The company has its presence across North America and Europe. The company has several owned subsidiaries involving PBH Australia Holdings Company Pty Limited (Australia), Practical Health Products, Inc (Delaware), Prestige Brands Holdings, Inc. (Virginia), Prestige Brands, Inc. (Delaware), Prestige Brands GmbH (Germany) among others.